glp-1 bulimia Agonist for Binge Eating Disorder: Evidence and Safety Use of glucagon‐like peptide‐1 receptor

The global prevalence of 537 million affected in the age group of 2079 years in 2021 will rise to 783 million in 2045, with the lowest increase in incidence in Europe (13%) and the highest in the African countries south of the Sahara (134%) ( Obesity, defined as a body mass index above 30 kg/m 2 , is also increasingly prevalent worldwide and has become a challenge to the various healthcare systems and societies

Nat Med 17: 14811489, 2011

Its a daily injection you dial up each time you use it

Taken from The Quantum Power of GLP-1 Peptides.

Here are some examples of GLP-1 agonists: Dulaglutide (marketed as Trulicity) Exenatide (marketed as Byetta and Bydureon) Liraglutide (marketed as Victoza) Lixisenatide (marketed as Adlyxin) Semaglutide (marketed as Ozempic and Rybelsus) Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis: The Glucagon-like Peptide-1 (GLP-1) Agonists Market size is estimated at USD 11.87 billion in 2023, and is expected to reach USD 12.55 billion by 2028, growing at a CAGR of 1.12% during the forecast period (2023-2028)

In addition, animal studies aimed at investigating the role of inflammatory pathways in the development of ARDS and acute lung injury (ALI) due to respiratory viral infections, such as influenza virus, highlighted the role of increased activity of inflammatory pathways of the hosts immune system in disease severity and cellular damages [73]